Claims for Patent: 9,296,815

Summary for Patent: 9,296,815

Title:	Antibodies with enhanced or suppressed effector function
Abstract:	Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components.
Inventor(s):	D\'Angelo; Igor (Port Moody, CA), Bleile; Dustin (Vancouver, CA), Tom-Yew; Stacey A. L. (New Westminster, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula I. (Vancouver, CA), Ohrn; Anders (Vancouver, CA), Poon; David K. Y. (Richmond, CA), Dixit; Surjit B. (Richmond, CA)
Assignee:	Zymeworks Inc. (Vancouver, British Columbia, CA)
Application Number:	13/638,362
Patent Claims:	1. A polypeptide comprising a variant Fc region, wherein said variant Fc region comprises amino acid modifications relative to a wild-type Fc region, said amino acid modifications comprising a mutation at position 239 and further comprises the mutation D265S, wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat, and wherein the mutation at position 239 is S239D or S239E. 2. The polypeptide of claim 1, wherein said modification at position 239 is S239E wherein the polypeptide has higher selectivity in binding to the Fc.gamma.RIIIa receptor compared to a polypeptide comprising the wild-type Fc region. 3. The polypeptide of claim 1, wherein said modifications further comprise the mutation S298A. 4. The polypeptide of claim 1 wherein the polypeptide comprises the amino acid modifications S239D/D265S/S298A/I332E S239E/D265S/H268D/I332E, or S239E/D265S/I332E. 5. The polypeptide of claim 1, wherein the variant Fc region is based on a human IgG Fc region. 6. The polypeptide of claim 5, wherein the human IgG Fc region is a human IgG1, IgG2, IgG3, or IgG4 Fc region. 7. The polypeptide of claim 1 wherein said polypeptide is an antibody. 8. The polypeptide of claim 7, wherein said antibody is a monoclonal antibody, a humanized antibody, or a human antibody. 9. A therapeutic antibody comprising the polypeptide of claim 1. 10. The therapeutic antibody of claim 9, wherein said therapeutic antibody is based on a parent antibody selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, VB4-847, girentuximab, ustekinumab, zalutumumab, and any other antibodies. 11. The therapeutic antibody of claim 9, wherein said therapeutic antibody binds to a target antigen selected from the group consisting of a-chain (CD25) of IL-2R, Amyloid beta, BLyS (or BAFF), CD11a, CD20, CD22, CD23, CD3, CD4, CD52, CD80, CTLA-4, EGFR, EpCAM, F protein of RSV, G250, glycoprotein IIb/IIIa R, HER2, Hsp90, IgE antibody, IL-12/IL-23, IL-1b, IL-5, IL-6 receptor, Integrin alpha-4/beta-1, Mucin 16/CA-125, RANKL, TNF alpha, and VEGF-A. 12. A pharmaceutical composition comprising a therapeutically effective amount of the polypeptide of claim 1, and a pharmaceutically acceptable carrier. 13. The polypeptide of claim 1 wherein the variant Fc region further comprises one or more mutations selected from the group consisting of: L234Q, L234N, L235A, G236E, E236L, E236D, G237F, G237N, S267E, S267D, S267G, H268D, H268E, E269L, E269L, D270N, D270I, D270E, S298A, K326A, K326D, A327H, A327V, A327L, A327T, A330V, A330L, A330W, A330I, A330S, I332L, I332D, and I332E. 14. The polypeptide of claim 1 wherein the variant Fc region further comprises one or more mutations selected from the group consisting of: S298A, K326A, K326D, A327H, A327V, A327L, A327T, I332L, I332D, and I332E.

Details for Patent 9,296,815

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-03-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-03-29
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2030-03-29
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2030-03-29
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2030-03-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2030-03-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2030-03-29